GFM
CSTL icon

GF Fund Management’s Castle Biosciences CSTL Stock Holding History

GF Fund Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Sell
631
-17
-3% -$379 ﹤0.01% 504
2026
Q1 		$15.9K Buy
648
+75
+13% +$2.46K ﹤0.01% 520
2025
Q4 		$22.3K Sell
573
-51
-8% -$1.64K ﹤0.01% 496
2025
Q3 		$14.2K Sell
624
-92
-13% -$1.87K ﹤0.01% 526
2025
Q2 		$14.6K Hold
716
– – ﹤0.01% 530
2025
Q1 		$14.3K Buy
716
+128
+22% +$3.17K ﹤0.01% 527
2024
Q4 		$15.7K Buy
+588
New +$17.9K ﹤0.01% 492

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GF Fund Management's CSTL Position: Q2 2026 in Review

GF Fund Management reduced its Castle Biosciences (CSTL) stake by 2.6% in Q2 2026, selling an estimated $379 and leaving 631 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #504.

GF Fund Management first reported a position in CSTL in Q4 2024 and has held it in 7 quarters since. The position peaked at $22.3K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • GF Fund Management held 631 shares of Castle Biosciences worth $15K as of Q2 2026.
  • GF Fund Management sold 17 Castle Biosciences shares in Q2 2026, an estimated $379.
  • Castle Biosciences made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #504 holding.
  • GF Fund Management first reported a position in Castle Biosciences in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Castle Biosciences position peaked at $22.3K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.